CON Stock Analysis: Concentra Holdings Parent | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 5.097m USD | 12M Return: 98.3% | US20603L1026 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 45.6M
Qual. Beats: 4
Rev. Trend: 94.6%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
Seasonality 2.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Concentra Group Holdings Parent, Inc. (NYSE: CON) is a U.S.-based provider of occupational health services operating through three segments: Occupational Health centers, Onsite health clinics, and Other business. Founded in 1979 and headquartered in Addison, Texas, the company offers a broad range of services including workers compensation care, employer-sponsored primary care, urgent care, injury care, preventive care, physical examinations, drug and alcohol screenings, vaccinations, and workplace hazard consultative services. The company also operates Concentra Telemed for remote treatment of work-related injuries, Concentra Pharmacy for repackaged medication distribution, and Concentra Medical Compliance Administration, a third-party administrator for employer drug-testing programs.
Concentra serves both employers and consumers, combining physical clinic locations with onsite workplace clinics and a mobile/telemedicine delivery model. As a mid-cap health care services company that went public in July 2024, it operates in a sector that also includes broader players in workforce health, primary care, and clinical testing, where scale, employer relationships, and integrated service offerings are key competitive factors.
- Workers compensation claim volumes drive core segment revenue
- Strong labor market fuels demand for occupational health services
- Onsite clinic expansion deepens employer relationships and recurring revenue
| Net Income: 198.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 5.04 > 1.0 |
| NWC/Revenue: 6.06% < 20% (prev 3.00%; Δ 3.06% < -1%) |
| CFO/TA 0.11 > 3% & CFO 335.5m > Net Income 198.7m |
| Net Debt (2.56b) to EBITDA (459.8m): 5.56 < 3 |
| Current Ratio: 1.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (128.2m) vs 12m ago 0.0% < -2% |
| Gross Margin: 29.31% > 18% (prev 29.92%; Δ -0.60% > 0.5%) |
| Asset Turnover: 78.18% > 50% (prev 70.60%; Δ 7.58% > 0%) |
| Interest Coverage Ratio: 3.54 > 6 (EBIT TTM 380.0m / Interest Expense TTM 107.3m) |
| A: 0.05 (Total Current Assets 506.5m - Total Current Liabilities 367.9m) / Total Assets 3.01b |
| B: 0.08 (Retained Earnings 244.2m / Total Assets 3.01b) |
| C: 0.13 (EBIT TTM 380.0m / Avg Total Assets 2.93b) |
| D: 0.19 (Book Value of Equity 477.1m / Total Liabilities 2.50b) |
| Altman-Z'' = 1.64 = BB |
| DSRI: 0.97 (Receivables 299.8m/271.8m, Revenue 2.29b/2.01b) |
| GMI: 1.02 (GM 29.92% / 29.31%) |
| AQI: 0.95 (AQ_t 0.58 / AQ_t-1 0.62) |
| SGI: 1.14 (Revenue 2.29b / 2.01b) |
| TATA: -0.05 (NI 198.7m - CFO 335.5m) / TA 3.01b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of October 29, 2026, the stock is trading at USD 40.59 with a total of 776,165 shares traded. Over the past week, the price has changed by +3.84%, over one month by +14.79%, over three months by +24.39% and over the past year by +98.27%.
Current recommended Stop Loss: 39.30 (which is 3.2% or 1.4 ATR below the current price).
Concentra Holdings Parent has received a consensus analysts rating of 4.78. Therefore, it is recommended to buy CON.
- StrongBuy: 7
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 42 | 3.5% |
P/E Trailing = 25.2975
P/E Forward = 18.018
P/S = 2.2282
P/B = 9.2987
Revenue TTM = 2.29b USD
EBIT TTM = 380.0m USD
EBITDA TTM = 459.8m USD
Long Term Debt = 1.56b USD (from longTermDebt, last quarter)
Short Term Debt = 99.6m USD (from shortTermDebt, last quarter)
Debt = 2.71b USD (from shortLongTermDebtTotal, last quarter) + Leases 570.2m
Net Debt = 2.56b USD (calculated: Debt 2.71b - CCE 158.0m)
Enterprise Value = 7.65b USD (5.10b + Debt 2.71b - CCE 158.0m)
Interest Coverage Ratio = 3.54 (Ebit TTM 380.0m / Interest Expense TTM 107.3m)
EV/FCF = 21.88x (Enterprise Value 7.65b / FCF TTM 349.8m)
FCF Yield = 4.57% (FCF TTM 349.8m / Enterprise Value 7.65b)
FCF Margin = 15.29% (FCF TTM 349.8m / Revenue TTM 2.29b)
Net Margin = 8.69% (Net Income TTM 198.7m / Revenue TTM 2.29b)
Gross Margin = 29.31% ((Revenue TTM 2.29b - Cost of Revenue TTM 1.62b) / Revenue TTM)
Gross Margin QoQ = 31.70% (prev 29.93%)
Tobins Q-Ratio = 2.54 (Enterprise Value 7.65b / Total Assets 3.01b)
Interest Expense / Debt = 3.95% (Interest Expense 107.3m / Debt 2.71b)
Taxrate = 23.15% (61.9m / 267.5m)
NOPAT = 292.1m (EBIT 380.0m * (1 - 23.15%))
Current Ratio = 1.38 (Total Current Assets 506.5m / Total Current Liabilities 367.9m)
Debt / Equity = 5.69 (Debt 2.71b / totalStockholderEquity, last quarter 477.1m)
Debt / EBITDA = 5.56 (Net Debt 2.56b / EBITDA 459.8m)
Debt / FCF = 7.31 (Net Debt 2.56b / FCF TTM 349.8m)
Total Stockholder Equity = 420.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.79% (Net Income 198.7m / Total Assets 3.01b)
RoE = 47.30% (Net Income TTM 198.7m / Total Stockholder Equity 420.1m)
RoCE = 19.18% (EBIT 380.0m / Capital Employed (Equity 420.1m + L.T.Debt 1.56b))
RoIC = 11.11% (NOPAT 292.1m / Invested Capital 2.63b)
WACC = 5.81% (E(5.10b)/V(7.81b) * Re(7.29%) + D(2.71b)/V(7.81b) * Rd(3.95%) * (1-Tc(0.23)))
Discount Rate = 7.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 77.15 | Cagr: 0.55%
[DCF] Terminal Value 77.97% ; FCFF base≈284.6m ; Y1≈326.3m ; Y5≈480.2m
[DCF] Fair Price = 36.62 (EV 7.23b - Net Debt 2.56b = Equity 4.67b / Shares 127.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 4
Revenue Correlation: 94.62 | Revenue CAGR: 8.49% | SUE: 1.72 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.44 | Chg30d=-0.25% | Revisions=+40% | Analysts=10
EPS current Year (2026-12-31): EPS=1.65 | Chg30d=-0.12% | Revisions=+40% | GrowthEPS=+20.3% | GrowthRev=+8.8%
EPS next Year (2027-12-31): EPS=1.84 | Chg30d=+0.18% | Revisions=+40% | GrowthEPS=+11.9% | GrowthRev=+6.0%
[Analyst] Revisions Ratio: +67% (up=6, down=0)